HFpEF in women needs holistic care targeting sex-specific risks, lifestyle, and novel therapies for better outcomes. Stimulant use can cause severe cardiomyopathy. Learn how “Heart Plus” bridges cardiology and addiction care. How do LVADs impact kidney function? Experts unpack the risks, benefits, and management of renal dysfunction in LVAD patients Challenging HFpEF cases? Learn diagnostic tips & guideline-based treatments from Dr. Jane Wilcox. OCT-derived virtual flow reserve predicts 2-year vessel failure post-PCI, adding physiologic insight to anatomic assessment. OCTIVUS shows PCI outcomes improve with EAPCI-defined stent optimization, regardless of imaging modality. MITT and safety data show acoramidis significantly lowers AFib-related events in transthyretin cardiac amyloidosis. LuX-Valve offers a safe, effective option for severe TR patients at high surgical risk. ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds. CTA-first screening before TAVR avoids invasive angiography in 53% of patients—without compromising outcomes. Delays in TAVI for acute decompensated aortic stenosis worsen outcomes. Explore evolving LV unloading strategies in AMI shock with The CardioNerds. Pulmonary air embolism causing RV failure & arrest—via ocular route? A rare case, deep dive, with The CardioNerds. NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research. The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis. Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM. Dr. Daniel Judge talks to the CardioNerds about a pivotal study in ATTR-CM. A multifaceted approach is necessary to reduce the deaths of smoking-related aortic aneurysms. Many preschool-aged children with congenital heart conditions are not on track for school readiness.